LncRNA DLX6-AS1 aggravates the development of ovarian cancer via modulating FHL2 by sponging miR-195-5p
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
LncRNA DLX6-AS1 aggravates the development of ovarian cancer via modulating FHL2 by sponging miR-195-5p
Authors
Keywords
-
Journal
Cancer Cell International
Volume 20, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-08-05
DOI
10.1186/s12935-020-01452-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- LncRNA UCA1-mediated Cdc42 signaling promotes oncolytic vaccinia virus cell-to-cell spread in ovarian cancer
- (2019) Kosuke Horita et al. Molecular Therapy-Oncolytics
- LncRNA DLX6-AS1 promotes tumor proliferation and metastasis in osteosarcoma through modulating miR-641/HOXA9 signaling pathway
- (2019) Ning Zhang et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- miR-340-FHL2 axis inhibits cell growth and metastasis in ovarian cancer
- (2019) Zheng Huang et al. Cell Death & Disease
- Linc00210 enhances the malignancy of thyroid cancer cells by modulating miR-195-5p/IGF1R/Akt axis
- (2019) Peijie Du et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Long noncoding RNA PVT1 : A highly dysregulated gene in malignancy
- (2019) Soudeh Ghafouri‐Fard et al. JOURNAL OF CELLULAR PHYSIOLOGY
- lncRNA SNHG1 cooperated with miR‐497/miR‐195‐5p to modify epithelial–mesenchymal transition underlying colorectal cancer exacerbation
- (2019) Jinghui Bai et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Down-regulated lncRNA DLX6-AS1 inhibits tumorigenesis through STAT3 signaling pathway by suppressing CADM1 promoter methylation in liver cancer stem cells
- (2019) Dong-Mei Wu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Overexpression of microRNA-195-5p reduces cisplatin resistance and angiogenesis in ovarian cancer by inhibiting the PSAT1-dependent GSK3β/β-catenin signaling pathway
- (2019) Jun Dai et al. Journal of Translational Medicine
- Long noncoding RNA DLEU1 aggravates glioma progression via the miR-421/MEF2D axis
- (2019) Li Feng et al. OncoTargets and Therapy
- Long noncoding RNA NORAD is upregulated in epithelial ovarian cancer and its downregulation suppressed cancer cell functions by competing with miR-155-5p
- (2019) Lingling Tong et al. Cancer Medicine
- A 3-Protein Expression Signature of Neuroblastoma for Outcome Prediction
- (2018) Yi Xie et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Enhanced expressions of FHL2 and iASPP predict poor prognosis in acute myeloid leukemia
- (2018) Zhiheng Cheng et al. CANCER GENE THERAPY
- Increased expression of FHL2 promotes tumorigenesis in cervical cancer and is correlated with poor prognosis
- (2018) Xuejing Jin et al. GENE
- Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries
- (2018) Claudia Allemani et al. LANCET
- Knockdown of lncRNA DLX6-AS1 inhibits cell proliferation, migration and invasion while promotes apoptosis by downregulating PRR11 expression and upregulating miR-144 in non-small cell lung cancer
- (2018) Yongjie Huang et al. BIOMEDICINE & PHARMACOTHERAPY
- miRNA and long non-coding RNA: molecular function and clinical value in breast and ovarian cancers
- (2018) Konstantina Panoutsopoulou et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- The long non-coding RNA MALAT1 promotes ovarian cancer progression by regulating RBFOX2-mediated alternative splicing
- (2018) Michael A. Gordon et al. MOLECULAR CARCINOGENESIS
- Emerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review
- (2017) Robert Cornelison et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The cardioprotective effect of melatonin and exendin-4 treatment in a rat model of cardiorenal syndrome
- (2016) Sarah Chua et al. JOURNAL OF PINEAL RESEARCH
- MicroRNA profiles in various hepatocellular carcinoma cell lines
- (2016) Asahiro Morishita et al. Oncology Letters
- Genetic and molecular changes in ovarian cancer
- (2016) Robert L Hollis et al. Cancer Biology & Medicine
- MicroRNA-195-5p, a new regulator of Fra-1, suppresses the migration and invasion of prostate cancer cells
- (2015) Jian Wu et al. Journal of Translational Medicine
- MicroRNA-195-5p acts as an anti-oncogene by targeting PHF19 in hepatocellular carcinoma
- (2015) HUI XU et al. ONCOLOGY REPORTS
- LncRNA: A link between RNA and cancer
- (2014) Guodong Yang et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- MicroRNA-195-5p is a potential diagnostic and therapeutic target for breast cancer
- (2014) QIFENG LUO et al. ONCOLOGY REPORTS
- Update on the management and the role of intraperitoneal chemotherapy for ovarian cancer
- (2013) Melissa C.C. Teo CURRENT OPINION IN OBSTETRICS & GYNECOLOGY
- Four-and-a-half LIM domains protein 2 (FHL2) is associated with the development of craniofacial musculature in the teleost fish Sparus aurata
- (2011) Marta S. Rafael et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Intracellular clusterin negatively regulates ovarian chemoresistance: compromised expression sensitizes ovarian cancer cells to paclitaxel
- (2011) Mohamed Kamel Hassan et al. TUMOR BIOLOGY
- MicroRNAs in ovarian cancer biology and therapy resistance
- (2010) Marijn T.M. van Jaarsveld et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Epithelial–mesenchymal transition in ovarian cancer
- (2009) Daniele Vergara et al. CANCER LETTERS
- Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung
- (2009) Ludmila Prudkin et al. MODERN PATHOLOGY
- The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs
- (2009) Ulrich Wellner et al. NATURE CELL BIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started